Patients with 22q11 deletion syndrome (22q11DS) have a high prevalence of psychiatric disorders and intellectual disability. At present the neurobiology underlying psychopathology in 22q11DS is still not understood. In the present study, we analyzed urinary serotonergic, dopaminergic and noradrenergic markers in 67 adults with 22q11DS. Levels of serotonin and the catecholamine metabolite homovanillic acid were significantly lower in the 22q11DS subjects compared to healthy controls. Within the 22q11DS group, levels of dopamine, homovanillic acid, norepinephrine, vanillyl mandelic acid and serotonin positively correlated with Full Scale Intelligence Quotient scores. Our results suggest that cognitive deficits in 22q11DS are associated with abnormal function of several neurotransmitters.
Introduction 22q11 deletion syndrome (22q11DS) is a genetic syndrome caused by a microdeletion on the long arm of chromosome 22. Since the first description it has been increasingly recognized and its prevalence is currently estimated to be 1:4000 (Oskarsdottir et al., 2004; McDonald McGinn and Sullivan, 2011) . The clinical picture is variable not only in terms of physical characteristics, but also for the highly prevalent cognitive deficits, behavioral and psychiatric problems (Hiroi et al., 2013; Jonas et al., 2014) . One of the most striking recent observations has been the dramatic cognitive and functional decline in some adults with 22q11DS (Evers et al., 2009 (Evers et al., , 2014 . Moreover, a recent study suggests that cognitive decline may start already in childhood (Duijff et al., 2012) . Idiopathic schizophrenia is often preceded by cognitive dysfunction prior to the onset of psychotic symptoms (Kahn and Keefe, 2013) .
Owing to the occurrence of several psychiatric disorders, in adulthood psychosis, anxiety and mood disorders particularly (Bassett et al., 2005; Tunbridge and Harrison, 2011) , it could be hypothesized that these are accompanied by a disruption of neurotransmitter systems that are known to be involved in these disorders (Nikolaus et al., 2010) .
The gene for catechol-O-methyl-transferase (COMT), an enzyme involved in the degradation of dopamine (DA) and norepinephrine (NE) , is located at 22q11, and therefore people with 22q11DS have a reduced gene dosage for COMT. We previously demonstrated reduced COMT expression (van Beveren et al., 2012) and disrupted dopaminergic neurotransmission in adult 22q11DS patients (Boot et al., 2008) . Thus, COMT hemizygosity in 22q11DS may have effect on catecholamine levels and thereby disturb brain function.
The role of DA in the development of psychotic symptoms in the general population is pivotal as is its role in cognitive dysfunction (most consistent finding is its role in working memory), in schizophrenia (Howes et al., 2012) . Its role in intelligence in general is less clear. Because of the high prevalence of psychosis in 22q11DS, research on this syndrome has particularly focused on the dopaminergic system.
Besides psychotic disorders, anxiety and mood disorders are also highly prevalent in patients with 22q11DS (Bassett et al., 2005; Nikolaus et al., 2010; Tunbridge and Harrison, 2011) . Central serotonergic abnormalities are thought to underlie these disorders as well as central dopaminergic and noradrenergic abnormalities (aan het Rot et al., 2009; Drago et al., 2011) . The combination of increased vulnerability to anxiety and mood disorders and the good treatment response to selective serotonergic re-uptake inhibitors (SSRIs) in 22q11DS (Stachon and De Souza, 2011 ) makes serotonin (5-hydroxy-tryptamine, 5-HT) involvement in the development of psychopathology in 22q11DS plausible. However, to the best of our knowledge the serotonergic system so far has not been investigated in 22q11DS.
The present study is the first to investigate serotonergic markers in adults with 22q11DS. In addition we report on dopaminergic and noradrenergic markers in a larger sample (n = 67) than we reported previously. By extending our original sample of adults (Boot et al., 2008 , we covered a broader range of psychiatric and cognitive symptoms and were able to address the complex interplay of mood, cognitive and psychotic symptoms that are present in 22q11DS.
This study has two research questions: (1) Do serotonergic, noradrenergic and dopaminergic markers differ between 22q11DS patients and controls? (2) Do these markers within the 22q11DS group correlate with cognitive functioning and other clinical outcome measures?
Patients and methods
The study was approved by the Medical Ethics Committee of the University of Maastricht, Maastricht and the University of Amsterdam, Amsterdam, The Netherlands and is part of a larger research project on neurotransmitter function in 22q11DS adults.
Participants were recruited through the Dutch 22q11DS family network, a specialized psychiatric 22q11DS outpatient clinic, and through several learning disability centers in the Netherlands. Patients with a confirmed deletion at chromosome 22q11.2 were included. Exclusion criteria were age below 18 and medical conditions affecting brain function, mimicking dementialike features such as Alzheimers dementia. Sixty-seven 22q11DS patients were included. All patients and/or their caretakers were informed about the study and written informed consent was obtained.
Healthy controls (n = 29) were recruited by advertisement.
Metabolic and clinical assessment

Metabolic measurements
Morning urine samples were collected for determination of DA, homo vanillic acid (HVA), NE, vanillyl mandelic acid (VMA), 3-methoxy-4-hydroxyphenylglycol (MHPG), 5-HT and 5-hydroxyindoleacetic acid (5-HIAA).
These compounds were determined using reversephase high-performance liquid chromatography (RP-HPLC) with fluorometric detection (Abeling et al., 1984; Stroomer et al., 1990) . For urinary levels of the biogenic amines and their metabolites, inter-assay variation, calculated on three different levels, ranged from 2.7 to 8.5%.
FSIQ measurements
Full Scale Intelligence Quotient (FSIQ) scores were obtained in the 22q11DS group using a shortened version of the Wechsler Adult Intelligence Scale (WAIS) version III (Wechsler, 2001) . Patients unable to perform a WAIS, were investigated using a Vineland-screener. The outcome of this test was converted to a FSIQ rating as described earlier (Kraijer and Plas, 2006) .
Psychopathology outcome measures
We determined whether anyone suffered from psychotic symptoms during life, based on information obtained from medical records and/or the present score on the Mini PAS-ADD, (Psychiatric Assessment Schedules for Adults with Developmental Disabilities) (Prosser et al., 1998) , MINI (Mini-International Neuropsychiatric Interview) (Sheehan et al., 1998) or PANSS (Positive And Negative Syndrome scale for Schizophrenia) (Kay et al., 1987) . Depressive symptomatology was determined using the Beck Depression Inventory (BDI) (Beck et al., 1996) and/or the depression score on the mini PAS-ADD. Depression scale values were dichotomized to determine if a patient fulfilled criteria for a depression (Beck et al., 1996; Prosser et al., 1998) .
Use of psychotropic drugs
The use of psychotropic drugs was noted and classified as antipsychotics, antidepressants and mood stabilizers.
Statistical analysis
All statistical analyses were performed using Stata version 12.1 (StataCorp., 2011). First, (crude) differences in age and metabolic outcomes between the groups (22q11DS or control) were examined using a t-test, whereas gender differences were analyzed using a chi-square test. After the crude analyses, the association between metabolic outcomes and group were analyzed using Analysis of Covariance (ANCOVA) in order to control for age and gender. To correct for multiple comparison the α was set at 0.007 (Bonferroni correction). Second, regression analyses were performed using data of the 22q11DS patients only. DA, HVA, NE, MHPG, VMA, 5-HT and 5-HIAA were employed as dependent variables in seven separate models. FSIQ was the main independent variable in all models. Presence of psychosis during life-time, age and gender were also included as independent variables. To explore the effect of use of psychotropic medication on metabolic outcomes in the patients with 22q11DS we added this factor in the regression analysis.
Results
Demographics
Forty-six percent (n = 31) of the 22q11DS group and 66% (n = 19) of the control group were male; this difference was statistically imprecise by conventional alpha (chi-square = 3.00, p = 0.08). Age (mean±S.D.) in the 22q11DS group was 35.0 years±10.9 and in the control group 30.8 years±9.7. This difference was also statistically imprecise by conventional alpha (t=−1.79, p = 0.08). Average FSIQ in the 22q11DS group was 52.3 ± 25.7 (range 7-96). Of the 67 patients with 22q11DS, 34 patients were treated with antipsychotic drugs; 12 were on antidepressants and 18 on mood stabilizers. Only 3 patients with a prescription for a mood stabilizer and/or antidepressant used no antipsychotic drugs. See Table 1 for use of psychotropic medication. None of the controls used psychotropic medication. Thirty-four patients had a history of psychosis and 11 patients would be diagnosed having a depression according to the scales used. Ten 22q11DS patients smoked tobacco(14.9%).
Metabolic outcomes per group
The concentration of excreted metabolites for both groups are presented in Table 2 . After correction for age and gender, urinary HVA and 5-HT concentrations were significantly lower in the 22q11DS group compared to controls.
Metabolic outcomes within the 22q11DS group
Within the 22q11DS group, regression analysis revealed that FSIQ was significantly associated with DA, HVA, NE, VMA and 5-HT excretion (Table 3) . Life-time presence of psychosis was only positively associated with NE. Age, gender and whether subjects scored positive for a depression, were not associated with any of the metabolic outcome measures.
The use of psychotropic medication did not change any of the results after regression analysis.
Discussion
Our findings indicate that FSIQ is associated with dopaminergic, noradrenergic and serotonin markers in adults with 22q11DS (Fig. 1) . In addition to previously reported disturbances in dopaminergic markers in 22q11DS, for the first time we report decreased urinary 5-HT concentrations in 22q11DS adults in comparison to healthy controls.
We previously reported elevated urinary DA levels and reduced metabolites (Boot et al., 2008) in a small, relatively young and healthy group of people with 22q11DS. This was thought to be the result of COMT haplo-insufficiency resulting in reduced degradation of DA. In our current extended study, however, we did not replicate our previous finding of increased DA levels. However, decreased DA and NE metabolites persisted, probably as a result of chronic reduced COMT activity. One possible explanation for our current findings could be a down-regulation of aromatic L-amino acid decarboxylase (AADC) also known as dopa decarboxylase (DDC) (Christenson et al., 1972) , owing to an assumed increased tonic DA activity which might result in reduced DA synthesis over time. AADC is the catalysing enzyme involved in the last step before formation of DA. In addition to DA, AADC is also the catalysing enzyme * Dopamine (DA), norepinephrine (NE) and 5-hydroxy-tryptamine (5-HT) in nmol/mmol kreat; homo vanillic acid (HVA), 3-methoxy-4-hydroxyphenylglycol (MHPG), vanillyl mandelic acid (VMA) and 5-hydroxyindoleacetic acid (5-HIAA) in mmol/mol kreat. ** After ANCOVA correction with age and gender ***p-value 40.007 (after Bonferroni correction).
involved in the last step before formation of 5-HT (Christenson et al., 1972) . By the same feedback mechanism as described above, a reduction of the AADC could lead to a decrease of 5-HT. This mechanism could also explain the good response to SSRIs in people with 22q11DS (Stachon and De Souza, 2011) . Another possible mechanism explaining reduced 5-HT in 22q11DS, could be related to a reduced gene dosage of SEPT5. The SEPT5 gene is also located at 22q11 and codes for septin-5, a protein important for active membrane movement such as vesicle trafficking and exocytosis in non-dividing cells as platelets and neurons (Bartsch et al., 2011) . Septin-5 is involved in 5-HT release in platelets (Dent et al., 2002) and the majority of 5-HT in the body is transported by platelets (Anderson et al., 1987) . As low platelet counts are frequently observed in people with 22q11DS, (Latger-Cannard et al., 2004; Saito et al., 2004) , this may indicate that the combination of reduced SEPT5 gene dosage, low platelet counts and, as a consequence, the observed low 5-HT levels are possibly related to each other. Results from studies in mice suggest that SEPT5 deficiency is related to psychiatric disorders seen in 22q11DS such as schizophrenia (Suzuki et al., 2009; Harper et al., 2012) . Thus, taken together we hypothesize that in 22q11DS reduced SEPT5 gene dosage as well as altered AADC activity secondary to reduced COMT activity may play a role in the development of psychopathology seen in 22q11DS. Further studies are requested to test these hypotheses. For example, studies may include imaging studies assessing AADC activity (Park et al., 2013) . Comparable research should be done for SEPT5 involvement to clarify our hypothesis.
All three neurotransmitters we studied were significantly related to FSIQ (Fig. 1) . They all three play an important role in the normal functioning brain with regards to cognitive abilities, especially in executive functioning (Robbins and Arnsten, 2009; Barnes et al., 2011) , learning and cognitive flexibility (Kehagia et al., 2010) . In addition, there have been recent reports of early-onset Parkinson's disease, a progressive neurodegenerative disorder, in 22q11DS (Zaleski et al., 2009; Booij et al., 2010; Butcher et al., 2013) . It is becoming increasingly clear that in Parkinson disease besides dopaminergic dysfunction, serotonergic abnormalities are responsible for mood and non-motor symptoms that are frequently seen in this disorder (Strecker et al., 2011; Drijgers et al., 2012; Politis et al., 2012) . In addition, the combined loss of dopaminergic and noradrenergic innervation of the limbic system is associated with cognitive and neurobehavioral problems (Delaville et al., 2011) . Low 5-HT levels have been associated with low DA in the substantia nigra (Fahn, 2008) and might be related to high prevalence of psychopathology (Fernandez, 2012) . Taken together, our results and the recent literature may suggest that a subgroup of adults with 22q11DS may be affected by a neurodegenerative process affecting at least three neurotransmitter systems. Besides ample knowledge of their role in 22q11DS in general, the precise mechanism in the clinical deterioration as seen in 22q11DS, has to be elucidated.
Strengths and limitations
The present study consisted of a relative large group of 22q11DS subjects.
The use of urinary markers is based on the assumptions that neurotransmitter synthesis, release, metabolism and neuronal activity are all linked and that these measurements, indirectly reflect (central) monoamine function (Amin et al., 1992 (Amin et al., , 1995 . However, many unrelated factors can confound these assessments when studying central monoamine systems. Nevertheless, peripheral monoamine (metabolite) levels may reflect (major) changes in the overall central monoamine turnover, and, hence, central monoamine function (Boot, 2010) . Previous observations of elevated DA levels in a smaller, healthier and slightly younger group of 22q11DS patients (Boot et al., 2008) may reflect an effect of medication in our current study, although introducing use of psychotropic medication as an independent variable did not change the results.
In conclusion, we report for the first time decreased 5-HT concentrations in 22q11DS adults in comparison to healthy controls. We also report an association between three neurotransmitter systems and cognitive functioning in 22q11DS patients. These findings require further studies investigating central neurotransmitter systems and its implications for psychopathology in 22q11DS.
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